Market Overview

UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at Hold; Royalty Burden High

Related INFI
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
3 Partnerships Pushing The Pharmaceutical Sector Forward

Stifel Nicolaus initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Hold rating.

Stifel Nicolaus noted, "Infinity's phosphoinositide-3-kinase (PI3K) inhibitor, IPI-145, has the potential to be a best-in-class drug for one of the most exciting targets in oncology and inflammation treatment. Preclinical data for IPI-145 as well as data from other drugs in development validate the PI3K target in our opinion as one that will provide strong efficacy in tumor resistance and inflammation reduction, while retaining a favorable safety profile. IPI-145 is the only dual PI3K delta and gamma inhibitor currently in clinical trials."

Infinity Pharmaceuticals closed at $17.74 on Thursday.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters